Pascal Soriot, AstraZeneca CEO (Raphael Lafargue/Abaca/Sipa USA; Sipa via AP Images)

April 30, 2021 10:31 AM EDTUpdated April 30, 10:19 PM

AstraZeneca's non-profit vaccine is, for now, costing them money

Jason Mast

Editor

For the first earnings report of the year, AstraZeneca invented a new metric: the profit they’d have if you didn’t count their Covid-19 vaccine costs …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca's non-profit vaccine is, for now, costing them money

Jason Mast

Editor

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Boehringer’s updated results in HER2-mutated lung cancer impress

Novavax responds to FDA’s trial ask, with Covid vaccine strain updates under scrutiny

GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer

Merck KGaA to buy rare cancer biotech SpringWorks for $3.9B

European regulators recommend new drugs from Vertex, Amgen and Jazz

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

As­traZeneca's non-prof­it vac­cine is, for now, cost­ing them mon­ey

Editor

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

AstraZeneca's non-profit vaccine is, for now, costing them money